drugset / Trial / NCT01902758

Drug Combination on Exercise Performance at High Altitude

NCT01902758

Phase 2/3 Completed 28 enrolled University of Montana
Non-randomizedParallel-groupTriple-blind

Summary

This study is being conducted to determine the effectiveness of using two FDA approved medications in concert to reduce the likelihood of sickness due to low oxygen levels and to reduce the decrement in physical performance at higher elevations. The investigators hypothesize that this drug combination will reduce the symptoms of acute mountain sickness and improve exercise performance at high altitude compared to placebo.

Timeline

Start
2013-08
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ambrisentan Small molecule 5 mg
Subject Theophylline Small molecule 400 mg